Inflammation and ovarian cancer

Cytokine

Volumn 58, Issue 2, 2012, Pages 133-147

  Macciò, Antonio ^a   Madeddu, Clelia ^b  

^a Sirai Hospital   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Anemia; Cancer cachexia; Inflammation; Interleukin 6; Ovarian cancer

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CARBOCISTEINE; CARNITINE; CELECOXIB; CISPLATIN; CURCUMIN; ICOSAPENTAENOIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; IRON; LACTOFERRIN; PACLITAXEL; POLYPHENOL; RECOMBINANT ERYTHROPOIETIN; RETINOL; SILTUXIMAB; STAT3 PROTEIN; THALIDOMIDE; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ANOREXIA; APOPTOSIS; CACHEXIA; CANCER GROWTH; CANCER PROGNOSIS; CANCER RELATED ANEMIA; CARCINOGENESIS; CYTOKINE PRODUCTION; DEPRESSION; DIET THERAPY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; ENERGY METABOLISM; EPITHELIAL OVARIAN CANCER; FATIGUE; HUMAN; HYPERBARIC OXYGEN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; WEIGHT REDUCTION;

CHEMOKINES; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84859219044     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.01.015     Document Type: Review

References (87)

1. Nowak M., Glowacka E., Szpakowski M., Szyllo K., Malinowski A., Kulig A., et al. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 2010, 31:375-383.
2. Clendenen T.V., Lundin E., Zeleniuch-Jacquotte A., Koenig K.L., Berrino F., Lukanova A., et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2011, 20:799-810.
3. Landen C.N., Birrer M.J., Sood A.K. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008, 26:995-1005.
4. Macciò A., Mantovani G., Turnu E., Artini P., Contu G., Volpe A. Preovulatory human follicular fluid in vitro inhibits interleukin (IL)-1 alpha, IL-2, and production and expression of p55 chain IL-2 receptor of lymphomonocytes. Fertil Steril 1994, 62:327-332.
5. Mantovani G., Macciò A., Massa E., Lai P., Manca G., Mudu C., et al. Relationships between Fas expression, activation molecule CD25, and functional activity of tumor-associated lymphomonocytes from neoplastic effusions. Oncol Rep 1999, 6:235-239.
6. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
7. Ferrandina G., Ranelletti F.O., Lauriola L., Fanfani F., Legge F., Mottolese M., et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 2002, 85:305-310.
8. Altinoz M.A., Korkmaz R. NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma 2004, 51:239-247.
9. Ali-Fehmi R., Semaan A., Sethi S., Arabi H., Bandyopadhyay S., Hussein Y.R., et al. Molecular typing of epithelial ovarian carcinomas using inflammatory markers. Cancer 2011, 117:301-309.
10. Lane D., Matte I., Rancourt C., Piché A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011, 11:210.
11. Rabinovich A., Medina L., Piura B., Segal S., Huleihel M. Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res 2007, 27:267-272.
12. Lo C.W., Chen M.W., Hsiao M., Wang S., Chen C.A., Hsiao S.M., et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 2011, 71:424-434.
13. Macciò A., Lai P., Santona M.C., Pagliara L., Melis G.B., Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1998, 69:248-252.
14. Sheu B.C., Chang W.C., Cheng C.Y., Lin H.H., Chang D.Y., Huang S.C. Cytokine regulation networks in the cancer microenvironment. Front Biosci 2008, 13:6255-6268.
15. Kulbe H., Chakravarty P., Leinster D.A., Charles K.A., Kwong J., Thompson R.G., et al. On behalf of the Australian Ovarian Cancer Study Group, M.A. Salako, J.F. Smyth, T. Hagemann, D.J. Brennan, D.D. Bowtell, F.R. Balkwill, a dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 2012, 72:66-75.
16. Coward J., Kulbe H., Chakravarty P., Leader D., Vassileva V., Leinster D.A., et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011, 17:6083-6096.
17. Rath K.S., Funk H.M., Bowling M.C., Richards W.E., Drew A.F., Expression of soluble interleukin-6 receptor in malignant ovarian tissue, Am J Obstet Gynecol 2010; 203:230.e1-8.
18. Min H., Wei-Hong Z. Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma. J Obstet Gynaecol Res 2009, 35:918-925.
19. Zhang X., Liu P., Zhang B., Wang A., Yang M. Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet 2010, 197:46-53.
20. Saydmohammed M., Joseph D., Syed V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J Cell Biochem 2010, 110:447-456.
21. Bast R.C., Boyer C.M., Jacobs I., Xu F.J., Wu S., Wiener J., et al. Cell growth regulation in epithelial ovarian cancer. Cancer 1993, 71:1597-1601.
22. Rosen D.G., Mercado-Uribe I., Yang G., Bast R.C., Amin H.M., Lai R., et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 2006, 107:2730-2740.
23. Colomiere M., Ward A.C., Riley C., Trenerry M.K., Cameron-Smith D., Findlay J., et al. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 2009, 100:134-144.
24. Mantovani G., Macciò A., Melis G., Mura L., Massa E., Mudu M.C. Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. Int J Cancer 2000, 86:842-847.
25. Mantovani G., Macciò A., Madeddu C., Mura L., Gramignano G., Lusso M.R., et al. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med (Berl) 2003, 81:664-673.
26. Robinson-Smith T.M., Isaacsohn I., Mercer C.A., Zhou M., Van Rooijen N., Husseinzadeh N., et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 2007, 67:5708-5716.
27. Jeannin P., Duluc D., Delneste Y. IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-γ. Immunotherapy 2011, 3:23-26.
28. Nowak M., Klink M., Glowacka E., Sulowska Z., Kulig A., Szpakowski M., et al. Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells. Scand J Immunol 2010, 71:91-98.
29. Cubillos-Ruiz J.R., Rutkowski M., Conejo-Garcia J.R. Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle 2010, 9:260-268.
30. Scarlett U.K., Cubillos-Ruiz J.R., Nesbeth Y.C., Martinez D.G., Engle X., Gewirtz A.T., et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 2009, 69:7329-7337.
31. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
32. Giuntoli R.L., Webb T.J., Zoso A., Rogers O., Diaz-Montes T.P., Bristow R.E., et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 2009, 29:2875-2884.
33. Kim A., Hagemann A., De Michele Immuno-modulatory gene polymorphisms and outcome in breast and ovarian cancer. Immunol Invest 2009, 38:324-340.
34. Yigit R., Massuger L.F., Figdor C.G., Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010, 117:366-372.
35. Napoletano C., Bellati F., Landi R., Pauselli S., Marchetti C., Visconti V., et al. Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med 2010, 14:2748-2759.
36. Leffers N., Gooden M.J., de Jong R.A., Hoogeboom B.N., Ten Hoor K.A., Hollema H., et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009, 58:449-459.
37. Gavalas N.G., Karadimou A., Dimopoulos M.A., Bamias A. Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol 2010, 2010:791603.
38. Wertel I., Nowicka A., Rogala E., Kotarski J. Peritoneal immune system in patients with advance epithelial ovarian cancer. Int Rev Immunol 2011, 30:87-101.
39. Thompson M.S., Mok S.C. Immunopathogenesis of ovarian cancer. Minerva Medica 2009, 100:357-370.
40. Macciò A., Madeddu C., Massa D., Astara G., Farci D., Melis G.B., et al. Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. J Cell Mol Med 2009, 13:3951-3959.
41. Scambia G., Testa U., Benedetti Panici P., Foti E., Martucci R., Gadducci A., et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995, 71:354-356.
42. Plante M., Rubin S.C., Wong G.Y., Federici M.G., Finstad C.L., Gastl G.A. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994, 73:1882-1888.
43. Liao S., Liu J., Lin P., Shi T., Jain R.K., Xu L. TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin Cancer Res 2011, 17:1415-1424.
44. Straub R.H., Cutolo M., Buttgereit F., Pongratz G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med 2010, 267:543-560.
45. Bennani-Baiti N., Davis M.P. MP, cytokines and cancer anorexia cachexia syndrome. Am J Hosp Palliat Care 2008, 25:407-411.
46. Mantovani G., Macciò A., Madeddu C., Mura L., Gramignano G., Lusso M.R., et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int. J. Cancer 2002, 98:84-91.
47. Argilés J.M., López-Soriano F.J. The role of cytokines in cancer cachexia. Med Res Rev 1999, 19:223-248.
48. Delano M.J., Moldawer L.L. The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract 2006, 21:68-81.
49. Hagemann T., Wilson J., Burke F., Kulbe H., Li N.F., Plüddemann A., et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 2006, 176:5023-5032.
50. Mantovani G., Macciò A., Massa E., Madeddu C. C, Managing cancer-related anorexia/cachexia. Drugs 2001, 61:499-514.
51. Mor G., Visintin I., Lai Y., Zhao H., Schwartz P., Rutherford T., et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005, 102:7677-7682.
52. Visintin I., Feng Z., Longton G., Ward D.C., Alvero A.B., Lai Y., et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008, 14:1065-1072.
53. Havel P.J. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004, 53:S143-S151.
54. Chan J.L., Heist K., DePaoli A.M., Veldhuis J.D., Mantzoros C.S. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest 2003, 111:1409-1421.
55. van Crevel R., Karyadi E., Netea M.G., Verhoef H., Nelwan R.H., West C.E., et al. Decreased plasma leptin concentrations in tuberculosis patients are associated with wasting and inflammation. J Clin Endocrinol Metab 2002, 87:758-763.
56. Macciò A., Madeddu C., Massa D., Mudu M.C., Lusso M.R., Gramignano G., et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 2005, 106:362-367.
57. van der Zee A.G., de Cuyper E.M., Limburg P.C., de Bruijn H.W., Hollema H., Bijzet J., et al. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer 1995, 75:1004-1009.
58. Takeda A., Toda T., Shinohara S., Mogi Y., Matsui N. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Am J Kidney Dis 2002, 40:104-109.
59. Costanzo E.S., Lutgendorf S.K., Sood A.K., Anderson B., Sorosky J., Lubaroff D.M. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 2005, 104:305-313.
60. Lutgendorf S.K., Weinrib A.Z., Penedo F., Russell D., DeGeest K., Costanzo E.S., et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 2008, 26:4820-4827.
61. Weinrib A.Z., Sephton S.E., Degeest K., Penedo F., Bender D., Zimmerman B., et al. Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer 2010, 116:4410-4419.
62. Lurie G., Thompson P.J., McDuffie K.E., Carney M.E., Goodman M.T. Prediagnostic symptoms of ovarian carcinoma: a case-control study. Gynecol Oncol 2009, 114:231-236.
63. Arriba L.N., Fader A.N., Frasure H.E., von Gruenigen V.E. A review of issues surrounding quality of life among women with ovarian cancer. Gynecol Oncol 2010, 119:390-396.
64. Smith L.H. Early clinical detection of ovarian cancer: a review of the evidence. Expert Rev Anticancer Ther 2006, 6:1045-1052.
65. Minton O., Richardson A., Sharpe M., Hotopf M., Stone P., Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 2010; 7:CD006704.
66. Monk J.P., Phillips G., Waite R., Kuhn J., Schaaf L.J., Otterson G.A., et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006, 24:1852-1859.
67. Carlson L.E., Speca M., Patel K.D., Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosom Med 2003, 65:571-581.
68. Fairey A.S., Courneya K.S., Field C.J., Bell G.J., Jones L.W., Mackey J.R. Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors. J Appl Physiol 2005, 98:1534-1540.
69. Stevinson C., Steed H., Faught W., Tonkin K., Vallance J.K., Ladha A.B., et al. Physical activity in ovarian cancer survivors: associations with fatigue, sleep, and psychosocial functioning. Int J Gynecol Cancer 2009, 19:73-78.
70. Wang Y., Niu X.L., Qu Y., Wu J., Zhu Y.Q., Sun W.J., et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010, 295:110-123.
71. Guo Y., Nemeth J., O'Brien C., Susa M., Liu X., Zhang Z., et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res 2010, 16:5759-5769.
72. Duan Z., Foster R., Bell D.A., Mahoney J., Wolak K., Vaidya A., et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006, 12:5055-5063.
73. Ferrandina G., Lauriola L., Zannoni G.F., Fagotti A., Fanfani F., Legge F., et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002, 13:1205-1211.
74. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
75. Yazlovitskaya E.M., Pelling J.C., Persons D.L. Association of apoptosis with the inhibition of extracellular signal-regulated protein kinase activity in the tumor necrosis factor alpha-resistant ovarian carcinoma cell line UCI 101. Mol Carcinog 1999, 25:14-20.
76. Chengedza S., Benbrook D.M. NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis. Anticancer Drugs 2010, 21:297-305.
77. Madoux F., Koenig M., Sessions H., Nelson E., Mercer B.A., Cameron M., Roush W., Frank D., Hodder P., Modulators of STAT transcription factors for the targeted therapy of cancer (STAT3 Inhibitors), probe reports from the NIH molecular libraries program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US) (2009) updated 2011 Mar 25.
78. Lavecchia A., Di Giovanni C., Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem 2011, 18:2359-2375.
79. Selvendiran K., Bratasz A., Kuppusamy M.L., Tazi M.F., Rivera B.K., Kuppusamy P. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer 2009, 125:2198-2204.
80. Selvendiran K., Kuppusamy M.L., Ahmed S., Bratasz A., Meenakshisundaram G., Rivera B.K., et al. Oxygenation inhibits ovarian tumor growth by downregulating STAT3 and cyclin-D1 expressions. Cancer Biol Ther 2010, 10:386-390.
81. Seo J.H., Jeong K.J., Oh W.J., Sul H.J., Sohn J.S., Kim Y.K., et al. Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer Lett 2010, 288:50-56.
82. MacDonald N. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. J Support Oncol 2007, 5:157-162.
83. Macciò A., Madeddu C., Gramignano G., Mulas C., Sanna E., Mantovani G. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist 2010, 15:894-902.
84. S.J. Clarke, J.T. Smith, C. Gebbie, C. Sweeney, N. Olszewski, A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer humanized anti-IL-6 antibody, in patients with advanced cancer, J. Clin. Oncol. 27, No. 15s (suppl) abstr 3025.
85. Bosaeus I. Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer 2008, 16:447-451.
86. Mantovani G., Macciò A., Madeddu C., Gramignano G., Lusso M.R., Serpe R., et al. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 2006, 15:1030-1034.
87. Mantovani G., Macciò A., Madeddu C., Serpe R., Massa E., Dessì M., et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010, 15:200-211.